{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:18:11Z","timestamp":1788247091777,"version":"build-2803163510"},"posted":{"date-parts":[[2026,5,6]]},"group-title":"In Review","reference-count":60,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,23]]},"abstract":"<title>Abstract<\/title>\n                <p>Myeloproliferative Neoplasms (MPNs) are rare hematologic neoplasms. The epidemiology and outcomes of these rare neoplasms warrant an update considering new diagnostic tools and advances in treatment options. NCI's Surveillance, Epidemiology and End Result (SEER)-17 registries were interrogated to analyze adult patients diagnosed with MPN [ICD-O-3 codes: polycythemia vera (PV) 9950\/3, essential thrombocythemia (ET) 9962\/3, primary myelofibrosis (PMF) 9961\/3, and chronic myeloid leukemia (CML) 9875\/3] during the years 2000 to 2021. Data of 63,242 (ET, n=24 172; PV, n= 23 456; PMF, n=6 131; CML, n=9 483) patients were analyzed. The overall incidence rate (IR) for ET, PV, PMF and CML was 1.8, 1.7, 0.5 and 0.7 per 100 000 person-years respectively. The incidence of ET, PV, and MF increased with age, and majority of cases were seen after the age of 50. 5-year Relative Survival (RS) for PMF was 50.9% in 2009, to 57.4% in 2013 and 60.6% in 2016. The median overall survival (OS) was 152 months for ET, 150 months for PV, 48 months for PMF, and 202 months for CML.  Advancing age was associated with adverse survival across MPN subtypes. Survival of patients with PMF continues to improve over recent years. Important racial and gender variations exist were noted in our study<\/p>","DOI":"10.21203\/rs.3.rs-9510524\/v1","type":"posted-content","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T10:14:36Z","timestamp":1778062476000},"source":"Crossref","is-referenced-by-count":0,"title":["Incidence, Prevalence, and Survival Outcomes of Patients with Myeloproliferative Neoplasms in the United States: a SEER database analysis, years 2000-2021"],"prefix":"10.21203","author":[{"given":"Pankit","family":"Vachhani","sequence":"first","affiliation":[{"name":"O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-8130","authenticated-orcid":false,"given":"Sachi","family":"Singhal","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Mishra","sequence":"additional","affiliation":[{"name":"Anne Arundel Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankalp","family":"Arora","sequence":"additional","affiliation":[{"name":"UT MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8835-8899","authenticated-orcid":false,"given":"Noha","family":"Sharafeldin","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Desai","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36(7):1703\u20131719.","journal-title":"Leukemia"},{"key":"ref2","volume-title":"Myeloproliferative Neoplasms. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025","author":"Thapa B","year":"2025","unstructured":"Thapa B, Fazal S, Parsi M, Rogers HJ. Myeloproliferative Neoplasms. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC., 2025."},{"issue":"7037","key":"ref3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James C","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144\u20131148.","journal-title":"Nature"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11899-009-0005-6","article-title":"The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis","volume":"4","author":"Thiele J","year":"2009","unstructured":"Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep. 2009;4(1):33\u201340.","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman Y","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.","journal-title":"PLoS Med"},{"issue":"25","key":"ref6","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms","volume":"369","author":"Klampfl T","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. New England Journal of Medicine. 2013;369(25):2379\u20132390.","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"ref7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic\u2009<\u2009i>CALR Mutations in Myeloproliferative Neoplasms with Nonmutated\u2009<\u2009i>JAK2","volume":"369","author":"Nangalia J","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, et al. Somatic\u2009<\u2009i>CALR Mutations in Myeloproliferative Neoplasms with Nonmutated\u2009<\u2009i>JAK2. New England Journal of Medicine. 2013;369(25):2391\u20132405.","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"ref8","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia","volume":"355","author":"Druker BJ","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, et al. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. New England Journal of Medicine. 2006;355(23):2408\u20132417.","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"ref9","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","volume":"362","author":"Kantarjian H","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine. 2010;362(24):2260\u20132270.","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"ref10","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia","volume":"362","author":"Saglio G","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine. 2010;362(24):2251\u20132259.","journal-title":"New England Journal of Medicine"},{"issue":"28","key":"ref11","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial","volume":"30","author":"Cortes JE","year":"2012","unstructured":"Cortes JE, Kim D-W, Kantarjian HM, et al. Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. Journal of Clinical Oncology. 2012;30(28):3486\u20133492.","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia","volume":"391","author":"Hochhaus A","year":"2024","unstructured":"Hochhaus A, Wang J, Kim D-W, et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine. 2024;391(10):885\u2013898.","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"ref13","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in Refractory Philadelphia Chromosome\u2013Positive Leukemias","volume":"367","author":"Cortes JE","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in Refractory Philadelphia Chromosome\u2013Positive Leukemias. New England Journal of Medicine. 2012;367(22):2075\u20132088.","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"Verstovsek S","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New England Journal of Medicine. 2012;366(9):799\u2013807.","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis","volume":"366","author":"Harrison C","year":"2012","unstructured":"Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine. 2012;366(9):787\u2013798.","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"e729-e740","DOI":"10.1016\/S2352-3026(24)00212-6","article-title":"Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"11","author":"Harrison CN","year":"2024","unstructured":"Harrison CN, Mesa R, Talpaz M, et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Haematology. 2024;11(10):e729-e740.","journal-title":"The Lancet Haematology"},{"issue":"Supplement 1","key":"ref17","doi-asserted-by":"crossref","first-page":"9592","DOI":"10.1182\/blood-2022-163456","article-title":"PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia","volume":"140","author":"Mascarenhas J","year":"2022","unstructured":"Mascarenhas J, Gerds AT, Kiladjian J-J, et al. PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia. Blood. 2022;140(Supplement 1):9592\u20139594.","journal-title":"Blood"},{"issue":"10373","key":"ref18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek S","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. The Lancet. 2023;401(10373):269\u2013280.","journal-title":"The Lancet"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States","volume":"63","author":"Verstovsek S","year":"2022","unstructured":"Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leukemia & Lymphoma. 2022;63(3):694\u2013702.","journal-title":"Leukemia & Lymphoma"},{"key":"ref20","unstructured":"Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975\u20132016, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2016\/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"100706","DOI":"10.1016\/j.blre.2020.100706","article-title":"Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map","volume":"42","author":"Shallis RM","year":"2020","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews. 2020;42(100706.","journal-title":"Blood Reviews"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-22-2628","article-title":"Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia","volume":"29","author":"Sweet KL","year":"2023","unstructured":"Sweet KL, Cortes JE, Apperley JF, et al. Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia. Clin Cancer Res. 2023;29(12):2179\u20132183.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"ref23","article-title":"New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options","volume":"57","author":"Penna D","year":"2021","unstructured":"Penna D. New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options. Medicina (Kaunas). 2021;57(11):","journal-title":"Medicina (Kaunas)"},{"key":"ref24","author":"Surveillance Epidemiology","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2023 Sub (2000\u20132021) - Linked To County Attributes - Time Dependent (1990\u20132022) Income\/Rurality, 1969\u20132022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024, based on the November 2023 submission. [cited; Available from: www.seer.cancer.gov"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajh.22212","article-title":"Environmental, lifestyle, and familial\/ethnic factors associated with myeloproliferative neoplasms","volume":"87","author":"Anderson LA","year":"2012","unstructured":"Anderson LA, Duncombe AS, Hughes M, Mills ME, Wilson JC, McMullin MF. Environmental, lifestyle, and familial\/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol. 2012;87(2):175\u2013182.","journal-title":"Am J Hematol"},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh GJ","year":"2014","unstructured":"Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. American Journal of Hematology. 2014;89(6):581\u2013587.","journal-title":"American Journal of Hematology"},{"issue":"23","key":"ref27","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/cncr.35038","article-title":"Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000\u20132019","volume":"129","author":"Sasaki K","year":"2023","unstructured":"Sasaki K, Haddad FG, Short NJ, et al. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000\u20132019. Cancer. 2023;129(23):3805\u20133814.","journal-title":"Cancer"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajh.21129","article-title":"Prevalence of polycythemia vera and essential thrombocythemia","volume":"83","author":"Ma X","year":"2008","unstructured":"Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA. Prevalence of polycythemia vera and essential thrombocythemia. American Journal of Hematology. 2008;83(5):359\u2013362.","journal-title":"American Journal of Hematology"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood.V110.11.4667.4667","article-title":"Prevalence of Polycythemia Vera and Essential Thrombocythemia","volume":"110","author":"Ma X","year":"2007","unstructured":"Ma X, Vanasse KGJ, Selinger HA, Wang Y, Cartmel B. Prevalence of Polycythemia Vera and Essential Thrombocythemia. Blood. 2007;110(11):4667\u20134667.","journal-title":"Blood"},{"issue":"21","key":"ref30","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1182\/blood.V120.21.2834.2834","article-title":"Epidemiology of Myeloproliferative Disorders in US - a Real World Analysis","volume":"120","author":"Mesa RA","year":"2012","unstructured":"Mesa RA, Mehta J, Wang H, et al. Epidemiology of Myeloproliferative Disorders in US - a Real World Analysis. Blood. 2012;120(21):2834.","journal-title":"Blood"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian H","year":"2012","unstructured":"Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119(9):1981\u20131987.","journal-title":"Blood"},{"issue":"Supplement 1","key":"ref32","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1182\/blood-2022-167855","article-title":"Trends in Frontline Treatment and Overall Survival in the Era of Targeted Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia","volume":"140","author":"Vardell VA","year":"2022","unstructured":"Vardell VA, Sobieski CE, Tantravahi SK. Trends in Frontline Treatment and Overall Survival in the Era of Targeted Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia. Blood. 2022;140(Supplement 1):6763\u20136764.","journal-title":"Blood"},{"issue":"24","key":"ref33","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz M","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30(24):2995\u20133001.","journal-title":"J Clin Oncol"},{"issue":"19","key":"ref34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16193257","article-title":"Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen-Single-Center Analysis","volume":"16","author":"Machherndl-Spandl S","year":"2024","unstructured":"Machherndl-Spandl S, Hannouf S, Nikoloudis A, et al. Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen-Single-Center Analysis. Cancers (Basel). 2024;16(19):","journal-title":"Cancers (Basel)"},{"issue":"8","key":"ref35","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/cncr.34103","article-title":"Improved survival of patients with myelofibrosis in the last decade: Single-center experience","volume":"128","author":"Masarova L","year":"2022","unstructured":"Masarova L, Bose P, Pemmaraju N, et al. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022;128(8):1658\u20131665.","journal-title":"Cancer"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.24882","article-title":"Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients","volume":"92","author":"Tefferi A","year":"2017","unstructured":"Tefferi A, Betti S, Barraco D, et al. Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. Am J Hematol. 2017;92(11):1193\u20131197.","journal-title":"Am J Hematol"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3324\/haematol.2016.149559","article-title":"Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group","volume":"102","author":"Geyer HL","year":"2017","unstructured":"Geyer HL, Kosiorek H, Dueck AC, et al. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica. 2017;102(1):85\u201393.","journal-title":"Haematologica"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi A","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189(2):291\u2013302.","journal-title":"Br J Haematol"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ajh.70065","article-title":"Triple A Plus (AAA (+)) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients","volume":"100","author":"Tefferi A","year":"2025","unstructured":"Tefferi A, Loscocco GG, Rokach L, et al. Triple A Plus (AAA (+)) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients. Am J Hematol. 2025;100(11):2017\u20132027.","journal-title":"Am J Hematol"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti F","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197\u20131201.","journal-title":"Blood"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/ajh.27079","article-title":"A globally applicable \"triple A\" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count","volume":"98","author":"Tefferi A","year":"2023","unstructured":"Tefferi A, Loscocco GG, Farrukh F, et al. A globally applicable \"triple A\" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. Am J Hematol. 2023;98(12):1829\u20131837.","journal-title":"Am J Hematol"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.25351","article-title":"20\u2009+\u2009Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients","volume":"94","author":"Penna D","year":"2019","unstructured":"Penna D, Lasho TL, Finke CM, et al. 20\u2009+\u2009Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. Am J Hematol. 2019;94(3):286\u2013290.","journal-title":"Am J Hematol"},{"issue":"7","key":"ref43","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein BL","year":"2010","unstructured":"Stein BL, Williams DM, Wang NY, et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica. 2010;95(7):1090\u20131097.","journal-title":"Haematologica"},{"issue":"9","key":"ref44","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1403141","article-title":"Two clinical phenotypes in polycythemia vera","volume":"371","author":"Spivak JL","year":"2014","unstructured":"Spivak JL, Considine M, Williams DM, et al. Two clinical phenotypes in polycythemia vera. N Engl J Med. 2014;371(9):808\u2013817.","journal-title":"N Engl J Med"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","article-title":"Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden","volume":"4","author":"Karantanos T","year":"2020","unstructured":"Karantanos T, Chaturvedi S, Braunstein EM, et al. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv. 2020;4(12):2567\u20132576.","journal-title":"Blood Adv"},{"issue":"6","key":"ref46","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bjh.17534","article-title":"Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes","volume":"193","author":"Karantanos T","year":"2021","unstructured":"Karantanos T, Gondek LP, Varadhan R, et al. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes. Br J Haematol. 2021;193(6):1142\u20131150.","journal-title":"Br J Haematol"},{"issue":"6","key":"ref47","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clml.2016.02.036","article-title":"Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms","volume":"16","author":"Khan I","year":"2016","unstructured":"Khan I, Shergill A, Saraf SL, et al. Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms. Clinical Lymphoma Myeloma and Leukemia. 2016;16(6):350\u2013357.","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"ref48","article-title":"Does race play a role in complications and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasms?","author":"Peseski AM","year":"2021","unstructured":"Peseski AM, Saliba AN, Althouse SK, Sayar H. Does race play a role in complications and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasms? Hematology\/Oncology and Stem Cell Therapy. 2021;","journal-title":"Hematology\/Oncology and Stem Cell Therapy"},{"issue":"3","key":"ref49","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour SA","year":"2016","unstructured":"Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol. 2016;174(3):382\u2013396.","journal-title":"Br J Haematol"},{"issue":"9","key":"ref50","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1007\/s00277-024-05894-7","article-title":"Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database","volume":"103","author":"Yan J","year":"2024","unstructured":"Yan J, Hammami MB, Wei JX, et al. Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database. Ann Hematol. 2024;103(9):3543\u20133551.","journal-title":"Ann Hematol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2024-194857","article-title":"Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis","volume":"144","author":"Palmer A","year":"2024","unstructured":"Palmer A, Rauscher G, Schoen A, et al. Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis. Blood. 2024;144(3794.","journal-title":"Blood"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1097\/HS9.0000000000000327","article-title":"Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms","volume":"4","author":"Duncombe AS","year":"2020","unstructured":"Duncombe AS, Anderson LA, James G, et al. Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms. Hemasphere. 2020;4(1):e327.","journal-title":"Hemasphere"},{"issue":"23","key":"ref53","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1182\/blood.V126.23.5561.5561","article-title":"Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States","volume":"126","author":"Parasuraman SV","year":"2015","unstructured":"Parasuraman SV, Naim AB, Paranagama DC, et al. Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States. Blood. 2015;126(23):5561.","journal-title":"Blood"},{"issue":"21","key":"ref54","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood.V124.21.3183.3183","article-title":"Impact of Myeloproliferative Neoplasms (MPNs) on Patients\u2019 Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States","volume":"124","author":"Mesa R","year":"2014","unstructured":"Mesa R, Miller CB, Thyne M, et al. Impact of Myeloproliferative Neoplasms (MPNs) on Patients\u2019 Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States. Blood. 2014;124(21):3183.","journal-title":"Blood"},{"issue":"1","key":"ref55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/ejh.12887","article-title":"Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms","volume":"99","author":"Goel S","year":"2017","unstructured":"Goel S, Paoli C, Iurlo A, et al. Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. European Journal of Haematology. 2017;99(1):36\u201341.","journal-title":"European Journal of Haematology"},{"issue":"23","key":"ref56","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/cncr.35038","article-title":"Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy\u2014The Surveillance, Epidemiology, and End Results database, 2000\u20132019","volume":"129","author":"Sasaki K","year":"2023","unstructured":"Sasaki K, Haddad FG, Short NJ, et al. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy\u2014The Surveillance, Epidemiology, and End Results database, 2000\u20132019. Cancer. 2023;129(23):3805\u20133814.","journal-title":"Cancer"},{"issue":"7","key":"ref57","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36(7):1703\u20131719.","journal-title":"Leukemia"},{"issue":"6","key":"ref58","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.12990","article-title":"WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes","volume":"166","author":"Alvarez-Larr\u00e1n A","year":"2014","unstructured":"Alvarez-Larr\u00e1n A, Ancochea A, Garc\u00eda M, et al. WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. Br J Haematol. 2014;166(6):911\u2013919.","journal-title":"Br J Haematol"},{"issue":"19","key":"ref59","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant M","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724\u20133734.","journal-title":"Blood"},{"issue":"3","key":"ref60","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta J","year":"2014","unstructured":"Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595\u2013600.","journal-title":"Leuk Lymphoma"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9510524\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9510524\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:06:31Z","timestamp":1788246391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9510524\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":60,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9510524\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41375-026-03124-9","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,5,6]]},"subtype":"preprint"}}